Biotechnology Fate Therapeutics Reports First Quarter 2022 Financial Results and Highlights Operational Progress May 4, 2022
Biotechnology Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the Association for Research in Vison and Ophthalmology Conference May 4, 2022
Search
biotech stock market
